Aims The angiotensin receptor‐neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val)
demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all …

Background Little information is available about the tolerability of uptitration to the maximal
dose of sacubitril/valsartan and the predictors and clinical correlates of achieving such a …

Heart failure (HF) is a progressive condition with an increasing prevalence, and the scientific
evidence of heart failure with reduced ejection fraction (HFrEF) reports a 6% rate of 1-year …

Background The angiotensin receptor-neprilysin inhibitor sacubitril/valsartan is known to
improve outcomes of cardiac death and hospitalization due to heart failure in patients with …

Abstract Aims Sacubitril/Valsartan (Sac/Val) was proven more effective than enalapril for
symptomatic patients with heart failure (HF) with reduced ejection fraction (HFrEF). This …

Despite significant advances in the last 30 years in reducing morbidity and mortality from
heart failure with reduced ejection fraction (HFrEF) with pharmacological and device-based …

Background Sacubitril/valsartan is an effective treatment for heart failure with reduced
ejection fraction (HFrEF) based on clinical trial data. However, little is known about its use or …

The clinical syndrome of heart failure (HF) can be described as the reduced capacity of the
heart to deliver blood throughout the body. To compensate for inadequate tissue perfusion …

Background In patients with heart failure with reduced ejection fraction (HFrEF), treatment
with sacubitril–valsartan (S/V) may reverse left ventricular remodeling (rLVR). Whether this …

Results Patients treated with sacubitril/valsartan in addition to beta-blocker and
mineralocorticoid receptor blocker were 68. Among them, 20 patients (29.4%), were …